心力衰竭的病变发生和治疗进展,使用保存的喷射分数
Xin Fan1,2, Jie Ma1,2, Xu Zhao1
1Department of Cardiology, Lanzhou University Second Hospital, 730030 Lanzhou, Gansu, China.
Reviews in cardiovascular medicine
|February 9, 2026
概括
心脏衰竭与保存的喷射分数 (HFpEF) 是常见的. 本综述详细介绍了HFpEF分子机制,如炎症和代谢问题,并讨论了这种心脏病的新疗法.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 病理生理学 病理生理学
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭是心力衰竭的主要类型.
- 研究正在转向 HFpEF 背后的分子机制.
- 关注的重点领域包括炎症,氧化应激,代谢失调和心脏顺应问题.
研究的目的:
- 审查了解HFpEF病变的最新进展.
- 总结HFpEF新兴的治疗策略.
- 为未来的诊断和管理方法提供见解.
主要方法:
- 对HFpEF最近研究的文献综述.
- 合成关于分子机制的信息.
- 对新型治疗策略的分析.
主要成果:
- HFpEF涉及复杂的分子通路,超出了传统的病理生理学.
- 炎症,氧化应激和代谢失调是至关重要的.
- 心脏顺应性受损,包括缩和纤维化是一个标志.
结论:
- 基于分子洞察力,新的治疗目标正在出现.
- 需要综合的方法,将传统和新疗法结合起来.
- 进一步的研究对于改善HFpEF诊断和管理至关重要.
相关概念视频
Heart Failure II: Pathophysiology
987
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
987
Pathophysiology of Heart Failure
3.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.9K
Heart Failure I: Introduction
937
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
937
Heart Failure VI: Adjunct Therapies
385
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
385
Heart Failure Drugs: Diuretics
1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure V: Medical Management
352
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
352


